BMT and Immunotherapies for Pediatric Leukemia


Current and novel treatments and financial implications        

Jointly planned by the National Marrow Donor Program®/Be The Match® and the Aplastic Anemia and MDS International Foundation.

Access on-demand slides

Download presentation slides 

Release date: June 10, 2019
Expiration date: June 10, 2021

Description

In this recorded webinar, you'll learn that bone marrow transplant (BMT) and immunotherapies continue to quickly evolve for pediatric leukemia, varying in the pathophysiology and management. For health professionals, knowledge of these treatment options and potential toxicities is necessary to manage and provide patients with safe and effective evidence-based care. When choosing these treatment options, families can face additional financial decisions and need assistance to manage the financial implications.

Learning Objectives

  • Define current BMT and immunotherapy agent outcomes with mechanisms of action used to treat pediatric leukemia
  • List the common side effects associated with immunotherapy and the supportive care needs for monitoring and educating patients and families
  • Examine financial burdens associated with BMT and immunotherapy
  • Identify educational resources available to assist in addressing a family’s information and financial needs

The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for pediatric patients with leukemia.

Speakers 

Vicki Szenes, MS, RN, CPNP, CPHON®   
Pediatric Nurse Practitioner 
Memorial Sloan-Kettering Cancer Center 

Victoria Szenes graduated from Binghamton University with a Bachelor of Art in Anthropology and a minor in the School of Management. She then received her Bachelor of Science in Nursing and later her Master of Science in Nursing in the Pediatric Nurse Practitioner program, both from Columbia University. She began her career as a clinical nurse in 2008 on the Pediatric Hematology/Oncology unit at Columbia- Presbyterian. After receiving her NP license she worked as a research nurse practitioner for the pediatric oncology team at Columbia University. In 2013, she joined the Pediatric Bone Marrow Transplant team at Memorial Sloan Kettering Cancer Center and currently serves as a clinical trials nurse practitioner.

Meghan Wellenbrink, BSN, RN, CPHON
CAR-T Cell Clinical Nurse Coordinator 
Memorial Sloan-Kettering Cancer Center

Meghan Wellenbrink is the CAR-T Cell Clinical Nurse Coordinator at Memorial Sloan-Kettering Cancer Center. I have been a nurse on the pediatric unit at Memorial for over seven years, the last of which has been primarily with the Bone Marrow Transplant Team focusing on the intake and management of CAR T Cell patients.

Target Audience

Hematology, oncology and BMT nurses; hematology, oncology and BMT social workers at intermediate to advanced levels of practice, experience and licensure; transplant center coordinators; payer case managers and other allied health professionals.

Certification

Participants must complete and submit the evaluation for the activity in order to receive a certificate of completion. 


AAMDS

Questions?

If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email nmdpeducation@nmdp.org

References

1. Yaniv I, Krauss AC, Beohu E, et al. Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children. Biol Blood Marrow Transplant.  2018; 24:1629-1642.

2. Im HJ. Current treatment for pediatric acute myeloid leukemia. Blood Res. 2018; 53(1):1-2. 

3. D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017. Available at: http://www.cibmtr.org

4. Warren CB.  Immunotherapy in Pediatric Oncology. Clin J Oncol Nurs. 2018;22(6):649-655. 

5. Bayer V, Amaya B, Baniewicz D, et al.  Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice. Clin J Oncol Nurs. 2017; 21(2):13-21. 

6. Blevins Primeau AS. Financial Toxicity and Cancer. Cancer Therapy Advisor.  Aug 2. 2018.

7. Bona K, London WB, Guo D, et al.  Prevalence and Impact of Financial Harship among New England Pediatric Stem cell Transplantation Families.  Biol Blood Marrow Transplant. 2015; 21:312-318.

8. Spencer JC, Samuel CA, Rosenstein DL, et al. Oncology navigators’ perceptions of cancer- related financial burden and financial assistance resources. Supportive Care in Cancer. 2018; 26(4):1315–1321.